Mechanism of acquired resistance to nivolumab in lung squamous cell carcinoma: case report and review of the literature.

Immunotherapy
Linying WuYuehong Wang

Abstract

Background: Immune checkpoint inhibitors targeting PD-1 and PD-L1 have noticeably improved the treatment landscape of advanced non-small-cell lung cancer, including lung squamous cell carcinoma (SCC). Although patients with immune checkpoint therapy can achieve long-term survival, acquired resistance has been recognized more frequently, while the underlying mechanisms are currently poorly understood. Materials and methods: Here, we report a patient with metastatic lung SCC treated with nivolumab as a first-line treatment for 28 months. Conclusion: The analysis of specimens prenivolumab and postnivolumab treatment suggests that genetic alterations in SOX2 and CDKN2A/CDKN2B and changes in the tumor microenvironment could be reasons for the acquired resistance to nivolumab observed in the lung SCC patient.

References

Apr 8, 2010·Cell Cycle·Thomas Hussenet, Stanislas du Manoir
Apr 5, 2011·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Theresia WilbertzSven Perner
Sep 28, 2013·Oncoimmunology·Kavita M DhodapkarMadhav V Dhodapkar
Jul 25, 2014·Nature Reviews. Cancer·Zhao ChenKwok-Kin Wong
Feb 20, 2015·Molecular Cancer Therapeutics·Sandip Pravin Patel, Razelle Kurzrock
Jun 2, 2015·The New England Journal of Medicine·James LarkinJedd D Wolchok
Jun 2, 2015·The New England Journal of Medicine·Julie BrahmerDavid R Spigel
Jul 20, 2016·The New England Journal of Medicine·Jesse M ZaretskyAntoni Ribas
Jul 28, 2016·Journal of Cancer Research and Therapeutics·Kozo KuribayashiTakashi Nakano
Dec 30, 2016·Cancer Discovery·Valsamo AnagnostouVictor E Velculescu
Feb 12, 2017·Cell·Padmanee SharmaAntoni Ribas
Feb 16, 2017·American Journal of Respiratory and Critical Care Medicine·Lúcia L CorreiaFrank M McCaughan
Jun 22, 2017·The New England Journal of Medicine·David P CarboneUNKNOWN CheckMate 026 Investigators
Aug 25, 2017·Molecular Cancer Therapeutics·Aaron M GoodmanRazelle Kurzrock
Mar 24, 2018·Science·Priscilla N Kelly
Mar 24, 2018·Science·Antoni Ribas, Jedd D Wolchok
Apr 17, 2018·The New England Journal of Medicine·Matthew D HellmannLuis Paz-Ares
Jun 20, 2018·Journal of the National Cancer Institute·Susanne HornAnnette Paschen
Oct 13, 2018·Science·Razvan CristescuDavid Kaufman
Jan 16, 2019·Nature Genetics·Robert M SamsteinLuc G T Morris
Feb 2, 2019·Nature Reviews. Clinical Oncology·Yosuke TogashiHiroyoshi Nishikawa
Mar 7, 2019·Molecular Cancer Therapeutics·Jennifer L GreenTyzoon Nomanbhoy
Jan 9, 2020·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Methods Mentioned

BETA
surgical resection
biopsy
whole-genome shotgun
xenograft

Software Mentioned

inForm
Vectra
FoundationOne

Related Concepts

Related Feeds

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.